Indian Council of Medical Research has said that COVID-19 vaccine Covaxin has equivalent immunogenicity against the UK-variant and circulating strains of SARS-Cov2 in India.
Covaxin is developed by Bharat Biotech in collaboration with ICMR. The UK-variant of SARS-Cov-2 with its all signature mutations were isolated and cultured in the world successfully for the first time at ICMR-NIV which was used for testing.
Support Ethical Journalism. Support The Dispatch
The Dispatch is a sincere effort in ethical journalism. Truth, Accuracy, Independence, Fairness, Impartiality, Humanity and Accountability are key elements of our editorial policy. But we are still not able to generate great stories, because we don’t have adequate resources. As more and more media falls into corporate and political control, informed citizens across the world are funding independent journalism initiatives. Here is your chance to support your local media startup and help independent journalism survive. Click the link below to make a payment of your choice and be a stakeholder in public spirited journalism